Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease
Bastiat G, Plourde F, Motulsky A, Furtos A, Dumont Y, Quirion R, Fuhrmann G, Leroux JC (2010)
Publication Type: Journal article
Publication year: 2010
Journal
Book Volume: 31
Pages Range: 6031-6038
Journal Issue: 23
DOI: 10.1016/j.biomaterials.2010.04.009
Abstract
Organogels can be prepared by immobilizing an organic phase into a three-dimensional network coming from the self-assembly of a low molecular weight gelator molecule. In this work, an injectable subcutaneous organogel system based on safflower oil and a modified-tyrosine organogelator was evaluated in vivo for the delivery of rivastigmine, an acetylcholinesterase (AChE) inhibitor used in the treatment of Alzheimer's disease. Different implant formulations were injected and the plasmatic drug concentration was assayed for up to 35 days. In parallel, the inhibition of AChE in different brain sections and the biocompatibility of the implants were monitored. The pharmacokinetic profiles were found to be influenced by the gel composition, injected dose and volume of the implant. The sustained delivery of rivastigmine was accompanied by a significant prolonged inhibition of AChE in the hippocampus, a brain structure involved in memory. The implant induced only a minimal to mild chronic inflammation and fibrosis, which was comparable to poly(d,. l-lactide-co-glycolide) in situ-forming implants. These findings suggest that tyrosine-based organogels could represent an alternative approach to current formulations for the sustained delivery of cholinesterase inhibitors. © 2010 Elsevier Ltd.
Authors with CRIS profile
Involved external institutions
Université de Montréal
Canada (CA)
McGill University
Canada (CA)
Eidgenössische Technische Hochschule Zürich (ETHZ) / Swiss Federal Institute of Technology in Zurich
Switzerland (CH)
Canada (CA)
McGill University
Canada (CA)
Eidgenössische Technische Hochschule Zürich (ETHZ) / Swiss Federal Institute of Technology in Zurich
Switzerland (CH)
How to cite
APA:
Bastiat, G., Plourde, F., Motulsky, A., Furtos, A., Dumont, Y., Quirion, R.,... Leroux, J.-C. (2010). Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease. Biomaterials, 31(23), 6031-6038. https://dx.doi.org/10.1016/j.biomaterials.2010.04.009
MLA:
Bastiat, Guillaume, et al. "Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease." Biomaterials 31.23 (2010): 6031-6038.
BibTeX: Download